GlassScriptPhysician profile
Stephen W Badolato
NPI 1194728832
$10,907.57
in general payments reported to CMS, 2019-2025
46 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 92% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $1,578 · 2021: $1,935 · 2022: $1,554 · 2023: $1,530 · 2024: $1,421 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,382.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,853.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $954.90 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amarin Pharma, INC. | $784.43 | 2019-2021 | |
| Lilly USA, LLC | $688.01 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $643.55 | 2019-2025 | Xarelto, Spravato |
| Phathom Pharmaceuticals, INC. | $577.37 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $534.95 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Novo Nordisk INC | $474.37 | 2019-2025 | Ozempic, Rybelsus |
| Avanir Pharmaceuticals, INC. | $362.16 | 2019 | |
| Pfizer INC. | $319.18 | 2019-2025 | |
| Astellas Pharma US INC | $295.29 | 2021-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $280.08 | 2020-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $247.12 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $246.22 | 2019-2023 | |
| Exact Sciences Corporation | $214.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Badolato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.